Related Experiment Video

Updated: Jul 3, 2026

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530

Y-M Chang1, L Bai, S Liu

  • 1Department of Urology, University of California at Davis, Sacramento, CA 95817, USA.

Oncogene
|August 6, 2008
PubMed

Insights

Src, a protein kinase, drives prostate cancer growth and migration. Inhibiting Src with AZD0530 significantly reduced tumor growth in mice, suggesting Src inhibition is a promising therapeutic strategy for prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Prostate cancer is the most common cancer in American men.
  • Src kinase activity promotes androgen-independent proliferation in prostate cancer.
  • Src family kinases (SFKs) are implicated in various cancers, including prostate cancer.

Purpose of the Study:

  • To investigate Src-mediated oncogenic pathways in prostate cancer using AZD0530, a novel SFK/Abl dual-kinase inhibitor.
  • To determine the efficacy of AZD0530 in inhibiting Src activation and downstream signaling.
  • To evaluate the therapeutic potential of AZD0530 in preclinical models of prostate cancer.

Main Methods:

  • Utilized prostate cancer cell lines (DU145, PC3) and orthotopic mouse xenograft models.
  • Assessed Src and Abl kinase expression and activation status.
  • Administered AZD0530 to inhibit Src activity and evaluated effects on cell cycle regulators (cyclin D1, c-Myc), cell motility factors (FAK, p130CAS, paxillin), and tumor growth.

Main Results:

  • Src, not Abl, is activated in prostate cancer cells.
  • AZD0530 rapidly and dose-dependently inhibited Src activation.
  • Src inhibition decreased cell proliferation by affecting G1 phase regulators and reduced cell motility.
  • AZD0530 administration reduced tumor growth in a xenograft model by 45%.

Conclusions:

  • Src kinase is a key mediator of prostate cancer cell proliferation and migration.
  • AZD0530 effectively inhibits Src activation and downstream oncogenic pathways.
  • Targeting Src with AZD0530 demonstrates significant preclinical efficacy, supporting its development as a novel prostate cancer therapy.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...